Oral Bee Venom as a Novel Therapeutic Approach for Diabetic Nephropathy in Rats:Role of PI3K, AMPK, and VEGF...

Diabetic nephropathy is a significant global health concern. While bee venom has shown potential in treating diabetes mellitus, its efficacy in managing diabetic nephropathy remains unclear. Moreover, the painful nature of bee venom injections besides its possible allergic reaction limits its widespread use. Thus, this study investigates the possible efficacy of oral bee venom administration compared to subcutaneous injection in treating diabetic nephropathy, focusing on the pathophysiological mechanisms involved. Thirty two rats were divided into four groups: normal control, diabetic control, subcutaneous bee venom (0.5 mg/kg daily), and oral bee venom (1 mg/kg in drinking water daily). Diabetes was induced in obese male albino rats using streptozotocin, followed by four weeks bee venom treatment. The present results revealed that the increased fasting glucose, insulin levels, HOMA-IR and serum creatinine in the diabetic control group, were restored to near-normal values with both bee venom-administration routes. Pi3K and AMPK, and the autophagy marker, Beclin-1, were downregulated in diabetic controls. Both bee venom treatments upregulated these genes. Additionally, immunohistochemistry revealed increased eNOS and VEGF in diabetic controls that decreased with both bee venom treatments. In conclusion. Oral bee venom effectively ameliorates diabetic nephropathy in rats through the upregulation of Pi3K, AMPK, Beclin-1, and decreased eNOS, and VEGF immunohistochemistry. Suggesting potential therapeutic applications for oral bee venom in managing diabetic nephropathy, offering a less painful and less allergic alternative to traditional subcutaneous administration.